Related Experiment Video
Updated: Jul 8, 2026
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
Blockade of p38 MAPK inhibits chronic allograft vasculopathy
Robert Ollinger1, Michael Thomas, Pamela Kogler
1Department of General and Transplant Surgery, D. Swarovski Research Lab, Medical University Innsbruck, Innsbruck, Austria. robert.oellinger@i-med.ac.at
Insights
Blocking p38 mitogen-activated protein kinase (MAPK) significantly reduces chronic allograft vasculopathy (CAV) in transplanted organs. This finding suggests p38 MAPK inhibition is a promising therapeutic strategy for preventing CAV after organ transplantation.
Area of Science:
- Immunology
- Vascular Biology
- Transplantation Science
Background:
- Chronic allograft vasculopathy (CAV) is a major cause of graft failure in solid-organ transplantation.
- CAV involves the proliferation of vascular smooth muscle cells, leading to arterial narrowing and graft dysfunction.
- Currently, no effective treatments exist to prevent CAV development.
Purpose of the Study:
- To investigate the potential of inhibiting p38 mitogen-activated protein kinase (MAPK) to prevent CAV.
- To test the hypothesis that in vivo p38 MAPK blockade can suppress CAV in a mouse model.
Main Methods:
- Utilized a mouse model of allogeneic aortic transplantation.
- Administered p38 MAPK inhibitors to assess their effect on CAV development.
- Monitored vascular changes and smooth muscle cell proliferation in the allografts.
Main Results:
- Pharmacological blockade of p38 MAPK markedly suppressed the development of CAV.
- Inhibition of p38 MAPK effectively reduced vascular smooth muscle cell proliferation within the graft arteries.
- The study demonstrated a significant protective effect of p38 MAPK blockade against CAV.
Conclusions:
- p38 MAPK signaling plays a critical role in the pathogenesis of CAV.
- Inhibition of p38 MAPK is a viable therapeutic strategy for preventing CAV.
- Clinical application of p38 MAPK blockade for CAV warrants further investigation.
Abstract:
Long-term survival after solid-organ transplantation is hampered by chronic changes in the arteries of the grafts, called chronic allograft vasculopathy (CAV). The lesions consist mainly of proliferating vascular smooth muscle cells that cause narrowing of the vessels; these lesions can develop within a few months. There is no effective treatment to prevent CAV. We previously noted that the pharmacological inhibition of p38 mitogen-activated protein kinase (MAPK) suppresses the proliferation of vascular smooth muscle cells. We hypothesized that in vivo inhibition of p38 MAPK in mice bearing allogeneic aortic allografts would prevent CAV. We here report that blockade of p38 MAPK, a signaling molecule involved in cell division, apoptosis, and cell death, markedly suppresses CAV. Given recent data indicating that inhibition of p38 MAPK is a promising approach for the treatment of autoimmune diseases plus our present findings, p38 MAPK blockade for CAV seems a reasonable approach to consider for clinical application.
